Drug Profile

RCT 2100

Alternative Names: Cystic fibrosis mRNA therapeutic - ReCode Therapeutics; RCT-2100

Latest Information Update: 09 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ReCode Therapeutics
Class Antifibrotics; RNA
Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cystic fibrosis
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Cystic fibrosis

Most Recent Events

28 Mar 2025 RCT 2100 receives Orphan Drug status for Cystic fibrosis in USA
27 Sep 2024 Pharmacodynamics data from a preclinical trial in Cystic fibrosis released by ReCode Therapeutics
21 Feb 2024 ReCode announces intention to submit IND to US FDA for Cystic fibrosis for a phase I trial of RCT 2100 in the first half of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com